MannKind to Present at Upcoming Conferences

November 2, 2009 5:00 PM EST

VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

    --  Imperial Capital's 3rd Annual Global Opportunities Conferenceon
        Thursday, November 5, 2009 at 2:10 PM (EST) at the New York Palace Hotel
        in New York, New York
    --  Lazard Capital Market's 6th Annual Healthcare Conferenceon Tuesday,
        November 17, 2009 at 2:10 PM (EST) at the St. Regis Hotel in New York,
        New York

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA(R), MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other programs are currently in Phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

    Source: MannKind Corporation

Related Categories

Press Releases

Stocks Mentioned

Related Entities

• Lazard

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?